Pharmaceutical - Somatuline

Filter

Current filters:

Somatuline

Popular Filters

Ipsen receives priority review for sNDA for Somatuline

Ipsen receives priority review for sNDA for Somatuline

01-09-2014

French drugmaker Ipsen has received priority review for its supplemental New Drug Application from the…

Gastroenteropancreatic neuroendocrine tumorsIpsenOncologyPharmaceuticalRegulationSomatulineUS Food and Drug AdministrationUSA

Ipsen files sNDA for Somatuline for GEP-NETs

Ipsen files sNDA for Somatuline for GEP-NETs

01-07-2014

French drugmaker Ipsen has submitted a Supplemental New Drug Application to the US Food and Drug Administration…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Ipsen sales up in first quarter, boosted by specialty care

Ipsen sales up in first quarter, boosted by specialty care

30-04-2014

French drugmaker Ipsen has reported sales of 305.9 million euros ($423 million) for the first quarter…

Business FinanceBusiness FinanceDecapeptylDysportEURFinancialFranceIpsenPfizerPharmaceuticalSomatulineTriptorelin

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

Ipsen hopes study results could lead to additional Somatuline indication

17-09-2013

French drugmaker Ipsen (Euronext: IPN) has released positive clinical trial results for the treatment…

EuropeIpsenNeurologicalPharmaceuticalResearchSomatuline

Trial finds Ipsen's tumor drug Somatuline superior to placebo in delaying disease progression

11-07-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive results from its Phase III study of Somatuline…

EuropeIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen reports mixed Ph III results with Somatuline Autogel in patients with acromegaly

18-06-2013

French drugmaker Ipsen (Euronext: IPN) announced the results of an international Phase IIIb study, PRIMARYS,…

IpsenPharmaceuticalRare diseasesResearchSomatuline

Global neuroendocrine carcinoma market to reach $475 million by 2019; report

04-07-2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market…

AvastinBioSynthemaIpsenLutatheraMarkets & MarketingOncologyPharmaceuticalRocheSomatuline

Teijin and Ipsen's Somatuline cleared in Japan

01-07-2012

Japanese drugmaker Teijin Pharma (TYO: 3402) revealed last Friday that it has received manufacturing…

Asia-PacificIpsenPharmaceuticalRare diseasesRegulationSomatulineTeijin

Back to top